GW Pharma takes back control of UK Sativex sales from Bayer

pharmafile | March 2, 2020 | News story | Sales and Marketing Bayer, GW Pharma, Sativex, UK 

British firm GW Pharmaceuticals has revealed that it plans to reclaim the commercialisation rights to market its cannabis-based multiple sclerosis drug Sativex (delta-9-tetrahydrocannabinol and cannabidiol), known by the generic name nabiximols, in the UK.

Previously, all sales in the UK of Sativex were exclusively managed by GW Pharma’s partner Bayer; this has been the case since the drug’s approval in 2010 by the

 Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of spasticity originating from multiple sclerosis.

However, this model will change going forward. As of the new arrangement agreed between GW and Bayer, there will be a “transitional period” until the end of this year, with GW assuming all commercialisation responsibilities relating to the sale of Sativex beyond 31 December 2020.

The pair committed to maintain “a seamless transition for health care professionals and patients” during this interim period, with no planned changes to day-to-day business practice.

Matt Fellows

Related Content


Long COVID: 15 studies launched with £19.6 million government funding

The UK government has announced the launch of 15 new extensive studies, backed by £19.6 …

Drugmakers fined a record £260 million after 10,000% drug price increase

The UK’s competition authority has issued its largest ever fine of more than £260 million …


New targeted lung cancer treatment coming to UK under MHRA scheme

The MHRA has issued an Early Access to Medicines Scheme (EAMS) positive scientific opinion for …

Latest content